Uncategorized

Trends in Antibiotics

I recently came across an interesting Brief from the Center for Healthcare Research and Transformation discussing antibiotics.  The Brief is titled Antibiotic Prescribing and Use.

The brief pulls data from a study based on Blue Cross Blue Shield members in Michigan but results are likely reflective of broader US trends.  Northwind clinics that offer medication dispensing will be interested in some of the findings.

Some interesting findings:

  • Overall antibiotic prescribing actually decreased from 2007-2009.
  • Antibiotic prescribing for children increased in the same period.

Top Ten Antibiotics:

  1. Azithromycin
  2. Amoxicillin
  3. Cephalexin
  4. Ciprofloxacin
  5. Amoxicillin-Clavulanate
  6. SMZ-TMP
  7. Doxycycline
  8. Levofloxacin
  9. Clindamycin
  10. Penicillin V

Azithromycin and Amoxicillin were prescribed much more frequently.  The list shifts a little  with children.

The brief also talks about appropriate prescribing habits and the challenges associated with inappropriate antibiotic use.  For clinic dispensing, awareness remains key as practitioners seek to address legitimate health concerns and the sometimes challenging emotional concerns of patients and the parents of patients.

As we head into another school year, antibiotics will again be at the top of the list for many ailments hitting us.  Applying antibiotic prescribing to bacterial infections and avoiding it for viral infections remains the best measure of "appropriate" (at least from the Brief’s perspective).  For point-of-care dispensing. the trends remain the same.  Offering the patient convenience while balancing their preferred treatment with the most effective approach remains a challenge.  Pharmaceutical wholesalers like Northwind remain a source of support but the balancing challenge remains with the practitioner.

For more information on this brief and some other interesting topics, check out the CHRT at www.chrt.org.

Schedule a free claims analysis now.

Let’s Talk now

New Drugs to Market – October Update

Phillip Berry | Oct 25th, 2024
The Food and Drug Administration (FDA) approved three novel drug therapies in October. One of those therapies,  Hympavzi (marstacimab-hncq), is a medication indicated for the treatment of patients with Hemophilia A and Hemophilia B. Hympavzi utilizes a new pathway to help reduce the risk of bleeding episodes in patients with Hemophilia, a disease that impacts … more »

continue reading

Letter From a Pharmacist – On Pharmacy Closures

Phillip Berry | Oct 25th, 2024
Pharmacists have a time-honored role as an integral contributor to the delivery of health care. From the earliest apothecaries to the retail stores of today, community pharmacists have provided guidance about health, wellness and medication therapy. Their expertise ranges from preventive care to the most advanced medications used in the treatment of complex disease.  Despite … more »

continue reading

Stewardship and the Beauty of Health Benefits

Phillip Berry | Oct 25th, 2024
The Beauty of Making a Difference Beauty in health benefits? What does that even mean? Think back on your experience as an HR/benefits professional. What are the peak moments? Most would agree that the high points are moments when they see their work directly impacting an employee or plan member. A time when the health … more »

continue reading